Royal Marsden Hospital, Sutton, UK.
J Neurooncol. 2011 Dec;105(3):467-74. doi: 10.1007/s11060-011-0661-y. Epub 2011 Jul 22.
Brain metastases (BM) are treated with surgical resection when feasible. Unfortunately this occurs only in a small subset of patients. The optimal treatment for patients with intracranial metastases non amenable to surgical resection has not been identified. Radiotherapy improves symptom control and survival but long-term local control has been poor. Conventional chemotherapies have generally produced disappointing results possibly due to their limited ability to penetrate the blood brain barrier. Therefore, newer treatments are required for patients with unresectable BM. Targeted therapies such as bevacizumab, erlotinib, gefitinib, sunitinib and sorafenib, are all licensed and have demonstrated improved survival in patients with metastatic disease. In this review we will present current data on targeted therapies that have been approved for the treatment of malignant tumours and we discuss the evidence of their use in patients with BM.
脑转移瘤（BM）在可行时采用手术切除治疗。不幸的是，只有一小部分患者适用这种方法。对于那些不能手术切除的颅内转移瘤患者，尚未确定最佳的治疗方法。放疗可以改善症状控制和生存情况，但长期局部控制效果不佳。传统化疗的效果通常令人失望，这可能是由于其穿过血脑屏障的能力有限。因此，对于不能手术切除的 BM 患者，需要新的治疗方法。贝伐珠单抗、厄洛替尼、吉非替尼、舒尼替尼和索拉非尼等靶向治疗方法均已获得批准，并已证明在转移性疾病患者中改善了生存情况。在这篇综述中，我们将介绍已批准用于恶性肿瘤治疗的靶向治疗药物的最新数据，并讨论其在 BM 患者中的应用证据。
